Captor Therapeutics Spolka Akcyjna (WSE:CTX)
Poland · Delayed Price · Currency is PLN 41.40
-0.60 (-1.43%)
Aug 14, 2025, 5:00 PM CET
Captor Therapeutics Spolka Akcyjna Company Description
Captor Therapeutics Spolka Akcyjna, a biopharmaceutical company, focuses on the discovery and development of protein degradation drugs for cancer and autoimmune diseases.
The company provides Targeted Protein Degradation technology that overcomes many existing drug limitations by removing proteins resistant to available therapeutics.
It has various therapeutic molecules in the preclinical stage. The company was incorporated in 2015 and is headquartered in Wroclaw, Poland.
Captor Therapeutics Spolka Akcyjna
| Country | Poland |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 91 |
| CEO | Michal Walczak |
Contact Details
Address: ul. Dunska 11 Wroclaw, 54-427 Poland | |
| Phone | 48 53 786 9089 |
| Website | captortherapeutics.com |
Stock Details
| Ticker Symbol | CTX |
| Exchange | Warsaw Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | PLN |
| ISIN Number | PLCPTRT00014 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Michal Walczak | Chief Executive Officer and Chief Scientific Officer |
| Sylvain Cottens | Co-Founder and Senior Vice President of Chemistry |
| Adam Lukojc | Chief Financial Officer |
| Anna Pawluk | Chief Operating Officer |
| Tomas Drmota | Chief Technology Officer |
| Marta Tomaszewska | Vice President of People and Culture |
| Dr. Thomas Shepherd Ph.D. | Senior Vice President of Strategy |
| Dr. Robert Dyjas | Head of Medical Affairs and Clinical Development |
| Dr. Andrew Saunders FFPM, M.D. | Chief Medical Officer |
| Dr. Anthony Rowen-Brown BSc., Dphil, M.B.A., Ph.D. | Chief Business Officer |